In order to assess as to whether or not the synthetic lethal interaction between c-myc and Bcl-xL inhibition can be utilized therapeutically, we employed a heterotopic model of glioblastoma, using p53 mutated LN229 cells. This evidence concerns the gene MYC and glioblastoma.